Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma

British Journal of Haematology

Volumn 152, Issue 5, 2011, Pages 593-599

  Ghosh, Nilanjan ^a   Ye, Xiaobu ^a   Ferguson, Anna ^a   Huff, Carol Ann ^a   Borrello, Ivan ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Bortezomib; Multiple myeloma; Thalidomide

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; STEROID; THALIDOMIDE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BEDTIME DOSAGE; CLINICAL ARTICLE; CONSTIPATION; CYTOGENETICS; DIARRHEA; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEMOLYTIC ANEMIA; HERPES ZOSTER; HUMAN; HYPOTENSION; IMMUNOHISTOCHEMISTRY; LEG CRAMP; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL TIME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DRUG ADMINISTRATION SCHEDULE; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PERIPHERAL NERVOUS SYSTEM DISEASES; PYRAZINES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 79951557067     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08534.x     Document Type: Article

References (28)

1. Adams, J., Palombella, V.J., Sausville, E.A., Johnson, J., Destree, A., Lazarus, D.D., Maas, J., Pien, C.S., Prakash, S. & Elliott, P.J. (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Research, 59, 2615-2622.
2. Cavo, M., Zamagni, E., Tosi, P., Cellini, C., Cangini, D., Tacchetti, P., Testoni, N., Tonelli, M., de Vivo, A., Palareti, G., Tura, S. & Baccarani, M. (2004) First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica, 89, 826-831.
3. Cavo, M., Patriarca, F., Tacchetti, P., Galli, M., Perrone, G., Petrucci, M.T., Brioli, A., Bringhen, S., Pantani, L., Tosi, P., Crippa, C., Zamagni, E., Di Raimondo, F., Narni, F., Cellini, C., Ceccolini, M., Pescosta, N., Goldaniga, M.C., Montefusco, V., Callea, V., De Stefano, V., Caravita, T., Boccadoro, M. & Baccarani, M. (2007) Bortezomib (Velcade(R))-thalidomide-dexamethasone (VTD) vs thalidomide-dexamethasone (TD) in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts), 110, 73.
4. Cavo, M., Tacchetti, P., Patriarca, F., Petrucci, M.T., Pantani, L., Galli, M., Raimondo, F.D., Crippa, C., Bringhen, S., Offidani, M., Narni, F., Montefusco, V., Zamagni, E., Spadano, T., Pescosta, N., Baldini, L., Cellini, C., Caravita, T., Ledda, A., Falcone, A., Tosi, P., Nozzoli, C., Zambello, R., Masini, L., Agostini, P., Fiacchini, M. & Baccarani, M. (2009) A phase III study of double autotransplantation incorporating bortezomib-thalidomide-dexamethasone (VTD) or thalidomide-dexamethasone (TD) for multiple myeloma: superior clinical outcomes with VTD compared to TD. Blood (ASH Annual Meeting Abstracts), 114, 351.
5. Chaudhry, V., Cornblath, D.R., Polydefkis, M., Ferguson, A. & Borrello, I. (2008) Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy. Journal of the Peripheral Nervous System, 13, 275-282.
6. Corso, A., Barbarano, L., Mangiacavalli, S., Montalbetti, L., Brasca, P., Zappasodi, P., Carella, A., Spriano, M., Alessandrino, E., Cairoli, R., Petrò, D., Varettoni, M., Bernasconi, P., Lazzarino, M. & Morra, E. (2007a) Bortezomib with high-dose dexamethasone as first line therapy in patients with multiple myeloma candidates to high-dose therapy. Blood, 110, 3595.
7. Durie, B.G., Harousseau, J.L., Miguel, J.S., Blade, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., Ludwig, H., Gahrton, G., Beksac, M., Crowley, J., Belch, A., Boccadaro, M., Cavo, M., Turesson, I., Joshua, D., Vesole, D., Kyle, R., Alexanian, R., Tricot, G., Attal, M., Merlini, G., Powles, R., Richardson, P., Shimizu, K., Tosi, P., Morgan, G. & Rajkumar, S.V. (2006) International uniform response criteria for multiple myeloma. Leukemia, 20, 1467-1473.
8. Fonseca, R., Blood, E., Rue, M., Harrington, D., Oken, M.M., Kyle, R.A., Dewald, G.W., Van Ness, B., Van Wier, S.A., Henderson, K.J., Bailey, R.J. & Greipp, P.R. (2003) Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood, 101, 4569-4575.
9. Gay, F., Brirnghen, S., Genuardi, M., Rossi, D., Ria, R., Romano, A., Ferrara, F., Di Renzo, N., Dominietto, A., Andriani, A., Rizzi, R., Vallone, R., Mele, G., Storti, S., Podda, L., Aitoro, G., Mettivier, V., Annibali, O., Rossini, F., Gentilini, P., Pavone, V., Giuliani, N., Rauco, A., Baraldi, A., Capaldi, A., Gherlinzoni, F., Gaidano, G., Boccadoro, M. & Palumbo, A. (2009) The weekly infusion of bortezomib reduces peripheral neuropathy. Blood (ASH Annual Meeting Abstracts), 114, 3887.
10. Harousseau, J.L., Attal, M., Leleu, X., Troncy, J., Pegourie, B., Stoppa, A.M., Hulin, C., Benboubker, L., Fuzibet, J.G., Renaud, M., Moreau, P. & Avet-Loiseau, H. (2006) Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica, 91, 1498-1505.
11. Harousseau, J.L., Mathiot, C., Attal, M., Marait, G., Caillot, D., Mohty, M., Hullin, C., Facon, T., Webb, I. & Moreau, P. (2007) VELCADE/Dexamethasone (Vel/D) versus VAD as induction treatment prior to autologous stem cell transplantion (ASCT) in newly diagnosed multiple myeloma (MM): updated results of the IFM 2005/01 trial. Blood, 110, 139a.
12. Harousseau, J.L., Avet-Loiseau, H., Facon, T., Attal, M., Doyen, C., Hulin, C., Garderet, L., Tiab, M., Lepeu, G., Aranjo, C., Cailliot, D., Petillon, m.-O., Mathiot, C., Mary, J.Y. & Moreau, P. (2009) Bortezomib plus dexamethasone (VD) versus reduced-dose bortezomib plus thalidomide plus dexametasone (vTD) as induction treatment prior to autologous stem-cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts), 114, 354.
13. Jagannath, S., Durie, B.G., Wolf, J., Camacho, E., Irwin, D., Lutzky, J., McKinley, M., Gabayan, E., Mazumder, A., Schenkein, D. & Crowley, J. (2005) Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. British Journal of Haematology, 129, 776-783.
14. Jagannath, S., Durie, B.G., Wolf, J., Camacho, E., Irwin, D., Lutzky, J., McKinley, M., Gabayan, E., Mazumder, A., Schenkein, D. & Crowley, J. (2006) Longterm follow up of patients treated with bortezomib alone or in combination with dexamethasone as frontline therapy for multiple myeloma. Blood, 108, 238a-239a.
15. Kaufman, J.L., Gleason, C., Heffner, L. & Lonial, S. (2007) Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma. Blood (ASH Annual Meeting Abstracts), 110, 3605.
16. Ludwig, H., Hajek, R., Tothova, E., Drach, J., Adam, Z., Labar, B., Egyed, M., Spicka, I., Gisslinger, H., Greil, R., Kuhn, I., Zojer, N. & Hinke, A. (2009) Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood, 113, 3435-3442.
17. Mateos, M.-V., Oriol, A., Martinez, J., Cibeira, M.T., Gutierrez, N.C., Terol, M.J., de Paz, R., Garcia-Larana, J., Bengoechea, E., Garcia-Sancho, A.M., Martinez, R., Palomera, L., de Arriba, F., Gonzalez, Y., Hernandez, J., Sureda, A., Bello, J.-L., Lahuerta, J.J., Blade, J. & San-Miguel, J.F. (2009) A prospective, multicenter, randomized, trial of bortezomib/melphalan/prednisone (VMP) versus bortezomib/thalidomide/prednisone (VTP) as induction therapy followed by maintenance treatment with bortezomib/thalidomide (VT) versus bortezomib/prednisone (VP) in elderly untreated patients with multiple myeloma older than 65years. Blood (ASH Annual Meeting Abstracts), 114, 3.
18. Mitsiades, N., Mitsiades, C.S., Poulaki, V., Chauhan, D., Richardson, P.G., Hideshima, T., Munshi, N.C., Treon, S.P. & Anderson, K.C. (2002) Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood, 99, 4525-4530.
19. Orlowski, R.Z., Stinchcombe, T.E., Mitchell, B.S., Shea, T.C., Baldwin, A.S., Stahl, S., Adams, J., Esseltine, D.L., Elliott, P.J., Pien, C.S., Guerciolini, R., Anderson, J.K., Depcik-Smith, N.D., Bhagat, R., Lehman, M.J., Novick, S.C., O'Connor, O.A. & Soignet, S.L. (2002) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. Journal of Clinical Oncology, 20, 4420-4427.
20. Rajkumar, S.V., Hayman, S., Gertz, M.A., Dispenzieri, A., Lacy, M.Q., Greipp, P.R., Geyer, S., Iturria, N., Fonseca, R., Lust, J.A., Kyle, R.A. & Witzig, T.E. (2002) Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. Journal of Clinical Oncology, 20, 4319-4323.
21. Rajkumar, S.V., Blood, E., Vesole, D., Fonseca, R. & Greipp, P.R. (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 24, 431-436.
22. Rajkumar, S.V., Rosinol, L., Hussein, M., Catalano, J., Jedrzejczak, W., Lucy, L., Olesnyckyj, M., Yu, Z., Knight, R., Zeldis, J.B. & Blade, J. (2008) Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. Journal of Clinical Oncology, 26, 2171-2177.
23. Rajkumar, S.V., Jacobus, S., Callander, N.S., Fonseca, R., Vesole, D.H., Williams, M.E., Abonour, R., Siegel, D.S., Katz, M. & Greipp, P.R. (2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncology, 11, 29-37.
24. Rosinol, L., Oriol, A., Mateos, M.V., Sureda, A., Garcia-Sanchez, P., Gutierrez, N., Alegre, A., Lahuerta, J.J., de la Rubia, J., Herrero, C., Liu, X., Van de Velde, H., San Miguel, J. & Blade, J. (2007) Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. Journal of Clinical Oncology, 25, 4452-4458.
25. Rummel, M.J., Niederle, N., Maschmeyer, G., Banat, A., Gruenhagen, U.v., Losem, C., Heil, G., Welslau, M., Balser, C., Kaiser, U., Ballo, H., Weidmann, E., Duerk, H.A., Kofahl-Krause, D., Roller, F., Barth, J., Hoelzer, D., Hinke, A. & Brugger, W. (2009) Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood (ASH Annual Meeting Abstracts), 114, 405.
26. San Miguel, J.F., Schlag, R., Khuageva, N.K., Dimopoulos, M.A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M.T., Palumbo, A., Samoilova, O.S., Dmoszynska, A., Abdulkadyrov, K.M., Schots, R., Jiang, B., Mateos, M.V., Anderson, K.C., Esseltine, D.L., Liu, K., Cakana, A., van de Velde, H. & Richardson, P.G. (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New England Journal of Medicine, 359, 906-917.
27. Sher, T., Miller, K.C., Ailawadhi, S., Manfredi, D., Wood, M., Tan, W., Wilding, G., Liu, H., Czuczman, M.S., Hernandez, F., Hong, F., Sood, R., Soniwalla, S., Lawrence, W., Kouides, P.A., Lee, K.P. & Chanan-Khan, A. (2009) Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide (VDT), an effective steroid independent regimen for previously untreated multiple myeloma patients: final result of a phase II study. Blood (ASH Annual Meeting Abstracts), 114, 618.
28. Wang, M., Giralt, S., Delasalle, K., Handy, B. & Alexanian, R. (2007) Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology, 12, 235-239.